Encycle Therapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 6
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $80M
Latest Deal Amount

Encycle Therapeutics General Information

Description

Developer of drugs designed to exploit a novel synthetic method to generate drug-like cyclic peptides. The company's drugs are generated by several scaffolds that are membrane permeable and orally bioavailable products, such as nacellins which are ideal for targeting protein-protein interactions, enabling patients to get cured from inflammatory bowel disease and other inflammatory disorders.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Primary Office
  • 101 College Street
  • Suite 314
  • Toronto, Ontario M5G 1L7
  • Canada
+1 (647) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Encycle Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 23-Oct-2019 $80M 00.000 0000 Completed Generating Revenue
5. Corporate 01-Nov-2017 00000 00.000 Completed Generating Revenue
4. Early Stage VC 30-Sep-2015 00.000 00.000 Completed Startup
3. Early Stage VC 16-Jun-2015 00000 00.000 Completed Startup
2. Grant 17-Nov-2014 $2.5M Completed Startup
1. Early Stage VC 11-Nov-2014 $2.5M $2.5M Completed Startup
To view Encycle Therapeutics’s complete valuation and funding history, request access »

Encycle Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of drugs designed to exploit a novel synthetic method to generate drug-like cyclic peptides. The company's dru
Drug Discovery
Toronto, Canada
6 As of 2015
00.000
000 0000-00-00
000000&0 00.000

00000000

nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor
0000 000000000
Vienna, Austria
00.000
00000000000 00.000

000000 0

ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in v
0000 000000000
South San Francisco, CA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Encycle Therapeutics Competitors (19)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apeptico Venture Capital-Backed Vienna, Austria 00.000 00000000000 00.000
000000 000000 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, United Kingdom 000 00000 000000000 00000
0000000 0000000000 Formerly VC-backed Boston, MA 0 00000 000000000 00000
000000 00000000000 Formerly VC-backed Boston, MA 000 00000 000000 - 000 00000
You’re viewing 5 of 19 competitors. Get the full list »

Encycle Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Encycle Therapeutics Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Accel-Rx Accelerator/Incubator Minority 000 0000 000000 0
BDC Capital Venture Capital Minority 000 0000 000000 0
CQDM Other Minority 000 0000 000000 0
MaRS Investment Accelerator Fund Venture Capital Minority 000 0000 000000 0
Merck & Co. Corporation 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »